The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Imetelstat in myelofibrosis: rationale, clinical evidence and ongoing trials
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, reviews imetelstat, which has shown favorable efficacy in higher-risk myelofibrosis and promising Phase II data in relapsed/refractory patients. Dr Kuykendall also notes that its potential for sequencing with ruxolitinib and its possible activity in patients with splicing mutations or ASXL1 wild-type disease remain underexplored. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
